BridGene Biosciences is a startup based in the United States, most recent round Series B, 1 tracked investor.
Based in the United States, BridGene Biosciences is a startup. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
BridGene Biosciences is a biotechnology company that discovers and develops small molecule drugs for traditionally "hard-to-drug" targets, utilizing its proprietary IMTAC™ chemoproteomic platform to identify novel binding sites and drug candidates for high-value targets in oncology and autoimmune diseases.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.